Resonance Specialities Ltd
Resonance Specialities Ltd is engaged in the business of manufacturing of chemicals like pyridine, picoline, cyanopyridine and their derivatives.[1]The company was formerly known as Armour Polymers Limited, was the first in India to manufacture Pyridines.
- Market Cap ₹ 117 Cr.
- Current Price ₹ 102
- High / Low ₹ 133 / 87.5
- Stock P/E 26.8
- Book Value ₹ 51.9
- Dividend Yield 0.00 %
- ROCE 7.26 %
- ROE 5.23 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- The company has delivered a poor sales growth of 5.78% over past five years.
- Company has a low return on equity of 12.9% over last 3 years.
- Debtor days have increased from 68.6 to 88.7 days.
- Promoter holding has decreased over last 3 years: -8.06%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
39.52 | 45.30 | 37.84 | 38.63 | 33.91 | 35.71 | 41.40 | 56.14 | 70.29 | 75.76 | 57.98 | 54.82 | 67.06 | |
37.36 | 42.19 | 36.59 | 35.62 | 31.89 | 35.06 | 36.51 | 48.39 | 56.04 | 59.01 | 51.15 | 49.94 | 60.26 | |
Operating Profit | 2.16 | 3.11 | 1.25 | 3.01 | 2.02 | 0.65 | 4.89 | 7.75 | 14.25 | 16.75 | 6.83 | 4.88 | 6.80 |
OPM % | 5.47% | 6.87% | 3.30% | 7.79% | 5.96% | 1.82% | 11.81% | 13.80% | 20.27% | 22.11% | 11.78% | 8.90% | 10.14% |
0.38 | -0.38 | 1.86 | 0.26 | 0.82 | 1.08 | 1.31 | 0.44 | 1.59 | 1.36 | 1.61 | 0.93 | 0.35 | |
Interest | 0.76 | 0.59 | 0.58 | 0.52 | 0.39 | 0.55 | 0.54 | 0.35 | 0.29 | 0.07 | 0.11 | 0.39 | 0.43 |
Depreciation | 1.15 | 1.10 | 1.16 | 1.12 | 1.06 | 1.15 | 0.91 | 0.92 | 0.98 | 1.75 | 1.48 | 1.46 | 1.72 |
Profit before tax | 0.63 | 1.04 | 1.37 | 1.63 | 1.39 | 0.03 | 4.75 | 6.92 | 14.57 | 16.29 | 6.85 | 3.96 | 5.00 |
Tax % | 25.40% | 0.96% | 7.30% | 27.61% | 25.90% | 2,700.00% | 32.63% | 20.38% | 27.73% | 24.06% | 27.01% | 25.00% | |
0.46 | 1.03 | 1.28 | 1.19 | 1.03 | -0.77 | 3.20 | 5.51 | 10.52 | 12.36 | 5.00 | 2.97 | 4.03 | |
EPS in Rs | 0.40 | 0.89 | 1.11 | 1.03 | 0.89 | -0.67 | 2.77 | 4.77 | 9.11 | 10.71 | 4.33 | 2.57 | 3.49 |
Dividend Payout % | 0.00% | 56.02% | 45.08% | 0.00% | 0.00% | 0.00% | 0.00% | 20.94% | 10.97% | 9.34% | 23.08% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 2% |
5 Years: | 6% |
3 Years: | -8% |
TTM: | 31% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | -2% |
3 Years: | -34% |
TTM: | 27% |
Stock Price CAGR | |
---|---|
10 Years: | 19% |
5 Years: | 26% |
3 Years: | -24% |
1 Year: | 5% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 17% |
3 Years: | 13% |
Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 |
Reserves | 9.42 | 9.45 | 9.95 | 11.14 | 12.42 | 11.72 | 14.93 | 18.99 | 29.13 | 40.26 | 44.15 | 45.95 | 48.33 |
3.45 | 3.38 | 3.12 | 1.92 | 4.07 | 3.40 | 0.00 | 0.00 | 0.72 | 0.09 | 2.29 | 4.17 | 3.84 | |
8.74 | 9.77 | 9.95 | 7.76 | 11.75 | 10.19 | 11.70 | 10.60 | 13.25 | 4.89 | 7.81 | 12.12 | 9.95 | |
Total Liabilities | 33.15 | 34.14 | 34.56 | 32.36 | 39.78 | 36.85 | 38.17 | 41.13 | 54.64 | 56.78 | 65.79 | 73.78 | 73.66 |
16.56 | 15.22 | 14.26 | 13.86 | 15.06 | 14.60 | 14.07 | 14.11 | 15.90 | 13.83 | 19.91 | 22.90 | 21.58 | |
CWIP | 0.03 | 0.03 | 0.03 | 0.13 | 0.20 | 0.60 | 0.83 | 1.84 | 0.04 | 0.44 | 0.44 | 0.32 | 0.58 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.75 | 0.12 | 0.00 | 2.81 | 5.94 |
16.56 | 18.89 | 20.27 | 18.37 | 24.52 | 21.65 | 23.27 | 25.08 | 37.95 | 42.39 | 45.44 | 47.75 | 45.56 | |
Total Assets | 33.15 | 34.14 | 34.56 | 32.36 | 39.78 | 36.85 | 38.17 | 41.13 | 54.64 | 56.78 | 65.79 | 73.78 | 73.66 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.79 | 1.76 | 1.11 | 3.23 | 0.56 | 2.14 | 5.27 | 1.42 | 4.28 | 13.33 | -8.37 | 4.16 | |
0.00 | -0.07 | -0.28 | -0.82 | -2.62 | -1.11 | -0.50 | -1.82 | -1.18 | -8.80 | 3.20 | -6.63 | |
-0.84 | -0.60 | -1.52 | -2.41 | 1.76 | -1.01 | -3.65 | 1.15 | 0.31 | -1.86 | 0.93 | 0.33 | |
Net Cash Flow | -0.05 | 1.09 | -0.69 | 0.01 | -0.30 | 0.02 | 1.11 | 0.76 | 3.42 | 2.66 | -4.24 | -2.13 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 70.75 | 76.63 | 99.16 | 66.05 | 79.76 | 67.97 | 66.74 | 39.92 | 48.92 | 39.51 | 77.68 | 88.69 |
Inventory Days | 105.52 | 81.52 | 133.71 | 159.21 | 397.20 | 211.58 | 180.17 | 232.12 | 236.12 | 175.79 | 646.44 | 340.53 |
Days Payable | 69.49 | 68.68 | 116.18 | 108.07 | 262.26 | 127.21 | 138.98 | 114.32 | 120.62 | 17.35 | 137.50 | 126.54 |
Cash Conversion Cycle | 106.78 | 89.46 | 116.69 | 117.19 | 214.70 | 152.35 | 107.93 | 157.71 | 164.41 | 197.94 | 586.62 | 302.67 |
Working Capital Days | 94.02 | 83.15 | 100.80 | 91.94 | 128.09 | 114.27 | 93.19 | 81.92 | 102.61 | 143.09 | 213.91 | 227.98 |
ROCE % | 5.70% | 7.30% | 3.96% | 8.74% | 6.84% | 2.23% | 20.21% | 30.63% | 41.32% | 34.91% | 12.65% | 7.26% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 24 Oct
- Financial Results For Q2 And H1 FY25 23 Oct
-
Board Meeting Outcome for Outcome Of Board Meeting Held On October 23, 2024.
23 Oct - Unaudited financial results for Q2 and half year ended September 30, 2024.
-
Board Meeting Intimation for Meeting Of Board Of The Company Will Be Held On Wednesday October 23, 2024 To Consider And Approve The Un-Audited Financial Results For The Quarter And Half Year Ended September 30, 2024.
9 Oct - Board meeting to approve Q2 financial results.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
8 Oct - Issue of duplicate share certificates to shareholders.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio[1]
The company manufactures and markets specialty chemicals based on pyridine chemistry such as Lutidine, cyano Pyridines, picoline, collidines, nutritional products, feed supplements, APIs, vitamins, etc. Pyridine
is segmented as Pyridine, Beta picoline, Alpha picoline, and Gamma picoline. The Asia-Pacific region is the largest market for pyridine.